Eli Lilly (LLY) rally comes under scrutiny as Novo Nordisk (NVO) readies key late-stage trial results for its GLP-1 pill ...

A new study has identified three existing medications that could be repurposed to treat or prevent Alzheimer's disease.

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Eli Lilly and Company (India) on Tuesday said it has received approval from national drug regulator CDSCO for a drug to treat ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Study found drugs used to prevent shingles and treat erectile dysfunction could be promising for Alzheimer’s patients ...

Researchers discovered that the common amino acid arginine can block harmful Aβ aggregation and reduce its toxic effects in ...

Novo's upcoming Alzheimer's trial results will test whether Rybelsus can slow cognitive decline and reshape treatment ...

Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...

In the early 1980s, men and women in the prime of their lives began arriving at Walter Reed Medical Center, wrecked by a ...

Alzheimer’s disease impacts tens of millions of families throughout the world, and projections state that more than 100 million people will be affected by the year 2050. The impact is not merely a ...